Recent Study from England’s National Health Service Highlights Positive Impact of Implementing HeartFlow’s FFRCT Analysis for Diagnosis of Coronary Artery Disease
Retrieved on:
Saturday, August 26, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Liverpool Heart and Chest Hospital, Percutaneous coronary intervention, Rare Diseases Clinical Research Network, National Health Service, FISH, NHS England, Non-fatal offences against the person in English law, CV, MI, Fractional flow reserve, Principal investigator, Cardiovascular disease, CAD, CRN, CCTA, MRC, European Society of Cardiology, PCI, Congress, Patient, Physician, Risk, CHIPS, Diagnosis, Mortality, ICA, NHS, Coronary artery disease, ESC, Medical device, Medical imaging, Pharmaceutical industry
The FISH&CHIPS study was designed to assess at a national level the incremental impact of adding HeartFlow FFRCT to a CCTA-first (Coronary Computed Tomography Angiography) diagnostic pathway to evaluate and manage CAD.
Key Points:
- The FISH&CHIPS study was designed to assess at a national level the incremental impact of adding HeartFlow FFRCT to a CCTA-first (Coronary Computed Tomography Angiography) diagnostic pathway to evaluate and manage CAD.
- FISH&CHIPS two-year key outcomes associated with availability of FFRCT include:
A significant 14% relative reduction in cardiovascular mortality and a significant 8% relative reduction in all-cause mortality. - An increase in cath lab efficiency, driven by a 5% relative reduction in invasive cardiac angiography (ICA) and an 8% relative increase in Percutaneous Coronary Intervention (PCI).
- High prognostic value for FFRCT whereby patients with severely abnormal FFRCT values (≤0.50) had a 2x risk of all-cause death and a 3x risk of non-fatal MI compared to patients with normal FFRCT values.